All In Biotech

Drug Trial Radar · NCT06524375

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

Phase II, Open-label, Prospective Single-arm, Multi-center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-treatment Period

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

118

Actual

Start

Aug 9, 2024

Primary completion

Oct 28, 2026

Study completion Jan 31, 2030

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • VenetoclaxDrug

    Venetoclax tablets will be administered as per the schedule specified in the arm.

  • cBTKi MonotherapyDrug

    Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. uMRD4 Rate at EOCTTime frame: Cycle 12 Day 28 (Cycle length= 28 Days)

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Springdale, Arkansas

  • Rocky Mountain Cancer Centers (Aurora) - USOR

    Aurora, Colorado

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Fort Wayne Medical Oncology and Hematology, Inc

    Fort Wayne, Indiana

  • Mission Blood and Cancer - MercyOne Cancer Center

    Des Moines, Iowa

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center

    Boston, Massachusetts

  • Nebraska Cancer Specialists St Francis - Grand Island

    Grand Island, Nebraska

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Astera Cancer Care East Brunswick

    East Brunswick, New Jersey

  • San Juan Oncology Associates, PC

    Farmington, New Mexico

  • Oncology Hematology Care Inc - Cincinnati - USOR

    Cincinnati, Ohio

  • Ohio State University

    Columbus, Ohio

  • Willamette Valley Cancer Institute and Research Center

    Eugene, Oregon

  • Asante Rogue Regional Medical Center

    Medford, Oregon

  • Tennessee Oncology, PLLC - Chattanooga

    Chattanooga, Tennessee

  • Tennessee Oncology - Midtown

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology- Northeast Texas

    Tyler, Texas

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.